Figures & data
Figure 1 Markov state-transition model with the seven proposed health states and possible transitions to be performed once for each screening method.
Abbreviation: IFG, impaired fasting glucose; T2D, type 2 diabetes mellitus.
![Figure 1 Markov state-transition model with the seven proposed health states and possible transitions to be performed once for each screening method.](/cms/asset/04276f6d-99fa-4a3d-b4d8-030051d43fd3/dceo_a_30547_f0001_c.jpg)
Figure 2 Markov model simulation for the impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada.
Abbreviations: IFG, impaired fasting glucose; TP, true positive test result; TN, true negative; FN, false negative; FP, false positive; T2DM, type 2 diabetes mellitus.
![Figure 2 Markov model simulation for the impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada.](/cms/asset/1feff7f4-0750-41c6-b1e4-87a95c8e264b/dceo_a_30547_f0002_b.jpg)
Table 1 Risk factors for type 2 diabetesTable Footnote1
Table 2 Base-case input values for the Markov modelTable Footnote1
Figure 3 Cost-effectiveness comparison between conventional screening for type 2 diabetes mellitus and no screening.
![Figure 3 Cost-effectiveness comparison between conventional screening for type 2 diabetes mellitus and no screening.](/cms/asset/0e89abeb-1e8a-4a7d-9f10-4b5d403e7415/dceo_a_30547_f0003_b.jpg)
Table 3 Sensitivity analysis and variation in frequency of screening
Figure 4 Cost-effectiveness acceptability curve for conventional screening for type 2 diabetes compared with “no screening” strategy.
![Figure 4 Cost-effectiveness acceptability curve for conventional screening for type 2 diabetes compared with “no screening” strategy.](/cms/asset/990c882e-597d-4829-b1aa-61ee06174cfe/dceo_a_30547_f0004_c.jpg)